I Mab (IMAB)

NASDAQ
Currency in USD
0.840
0.000(0.00%)
Closed
After Hours
0.830-0.010(-1.19%)
IMAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 11 days
Fair Value
Day's Range
0.8300.894
52 wk Range
0.7602.000
Key Statistics
Edit
Prev. Close
0.84
Open
0.83
Day's Range
0.83-0.894
52 wk Range
0.76-2
Volume
510.11K
Average Volume (3m)
400.22K
1-Year Change
-53.33%
Book Value / Share
2.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMAB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
5.750
Upside
+584.52%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

I Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Employees
34

Compare IMAB to Peers and Sector

Metrics to compare
IMAB
Peers
Sector
Relationship
P/E Ratio
−0.8x−2.5x−0.5x
PEG Ratio
−0.01−0.020.00
Price/Book
0.3x1.4x2.6x
Price / LTM Sales
120.1x23.9x3.0x
Upside (Analyst Target)
-201.3%56.3%
Fair Value Upside
Unlock18.4%10.0%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.750
(+584.52% Upside)

Earnings

Latest Release
Nov 14, 2024
EPS / Forecast
-0.11 / -0.07
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the I Mab (IMAB) Stock Price Today?

The I Mab stock price today is 0.84.

What Stock Exchange Does I Mab Trade On?

I Mab is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for I Mab?

The stock symbol for I Mab is "IMAB."

What Is the I Mab Market Cap?

As of today, I Mab market cap is 68.40M.

What is I Mab Earnings Per Share?

The I Mab EPS is -0.766.

What Is the Next I Mab Earnings Date?

I Mab will release its next earnings report on 25 Mar 2025.

From a Technical Analysis Perspective, Is IMAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.